Hypereosinophilic Syndrome- Pipeline Insight, 2022

Hypereosinophilic Syndrome- Pipeline Insight, 2022

DelveInsight’s, “Hypereosinophilic Syndrome- Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hypereosinophilic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Hypereosinophilic Syndrome: Understanding Hypereosinophilic Syndrome: Overview Hypereosinophilic (hy-per-ee-o-sin-o-FILL-ick) syndrome (HES) is a group of rare blood disorders. It occurs when an individual's blood has very high numbers of eosinophils. An eosinophil is a type of white blood cell that plays an important role in the immune system. Most people have less than 500 eosinophils/microliter in their blood. People with HES usually have more than 1,500 eosinophils/microliter in their blood for 6 months or more, and the cause cannot be identified. These eosinophils make their way into various tissues, causing inflammation and eventually organ dysfunction. The most commonly involved organs in HES include the skin, lungs, heart and nervous system. Signs and symptoms vary significantly based on which parts of the body are affected. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected. The condition was originally thought to be "idiopathic" or of unknown cause. However, recent advances in diagnostic testing have allowed a cause to be identified in approximately a quarter of cases. HES can happen at any age, although it is more common in adults. People with HES may suffer from a wide variety of symptoms, depending upon which parts of the body are affected. These symptoms include: Skin rashes such as urticaria or angioedema, dizziness, memory loss or confusion, cough, shortness of breath, fatigue, fever and mouth sores. Symptoms of HES are also common in many other medical problems, making an initial diagnosis more difficult. The first step is to rule out other conditions with similar symptoms. These include parasitic infection, allergic disease, cancers, autoimmune diseases and drug reactions. An allergist / immunologist has specialized training to effectively diagnose the problem and, if HES is present, to work collaboratively with other specialists such as a hematologist or cardiologist in the treatment and monitoring of HES. The goal of HES treatment is to reduce eosinophil levels in the blood and tissues, thereby preventing tissue damage–especially in the heart. Standard HES treatment includes glucocorticosteroid medications such as prednisone, and chemotherapeutic agents such as hydroxyurea, chlorambucil and vincristine. Interferon-alpha may also be used as a treatment. This medication must be administered by frequent injections. “Hypereosinophilic Syndrome- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypereosinophilic Syndrome pipeline landscape is provided which includes the disease overview and Hypereosinophilic Syndrome treatment guidelines. The assessment part of the report embraces, in depth Hypereosinophilic Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypereosinophilic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Hypereosinophilic Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Hypereosinophilic Syndrome. Hypereosinophilic Syndrome Emerging Drugs Chapters This segment of the Hypereosinophilic Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Hypereosinophilic Syndrome Emerging Drugs • Benralizumab: Kyowa Kirin Benralizumab is a monoclonal antibody that attracts natural killer cells via antibody-dependent cellular cytotoxicity activity (ADCC activity) to induce direct and rapid depletion of eosinophils in the blood and in the airway. Benralizumab is available as a fixed-dose subcutaneous injection via a prefilled syringe administered once every 4 weeks for the first 3 doses, and then once every 8-weeks thereafter. Benralizumab is also being studied in severe nasal polyposis. The U.S Food and Drug Administration recently granted benralizumab orphan drug designation for hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA).Benralizumab was licensed to AstraZeneca from BioWa, Inc., a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd., and developed by Kyowa Hakko Kirin and AstraZeneca. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hypereosinophilic Syndrome. • Depemokimab: GlaxoSmithKline Depemokimab (GSK3511294), is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hypereosinophilic Syndrome. Further product details are provided in the report…….. Hypereosinophilic Syndrome: Therapeutic Assessment This segment of the report provides insights about the different Hypereosinophilic Syndrome drugs segregated based on following parameters that define the scope of the report, such as: • Major Players in Hypereosinophilic Syndrome There are approx. 5+ key companies which are developing the therapies for Hypereosinophilic Syndrome. The companies which have their Hypereosinophilic Syndrome drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline. • Phases DelveInsight’s report covers around 5+ products under different phases of clinical development like • Late stage products (Phase III) • Mid-stage products (Phase II) • Early-stage product (Phase I) along with the details of • Pre-clinical and Discovery stage candidates • Discontinued & Inactive candidates • Route of Administration Hypereosinophilic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as • Intra-articular • Intraocular • Intrathecal • Intravenous • Ophthalmic • Oral • Parenteral • Subcutaneous • Topical • Transdermal • Molecule Type Products have been categorized under various Molecule types such as • Oligonucleotide • Peptide • Small molecule • Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Hypereosinophilic Syndrome: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypereosinophilic Syndrome therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypereosinophilic Syndrome drugs. Hypereosinophilic Syndrome Report Insights • Hypereosinophilic Syndrome Pipeline Analysis • Therapeutic Assessment • Unmet Needs • Impact of Drugs Hypereosinophilic Syndrome Report Assessment • Pipeline Product Profiles • Therapeutic Assessment • Pipeline Assessment • Inactive drugs assessment • Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: • How many companies are developing Hypereosinophilic Syndrome drugs? • How many Hypereosinophilic Syndrome drugs are developed by each company? • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypereosinophilic Syndrome? • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypereosinophilic Syndrome therapeutics? • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? • What are the clinical studies going on for Hypereosinophilic Syndrome and their status? • What are the key designations that have been granted to the emerging drugs? Key Players • Kyowa Kirin • GlaxoSmithKline • Novartis Pharmaceuticals Corporation • Dexpramipexole Key Products • Benralizumab • Depemokimab • Nilotinib • Knopp Biosciences

Please Note: It will take 7-10 business days to complete the report upon order confirmation.